<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433472</url>
  </required_header>
  <id_info>
    <org_study_id>NABTT-2002 CDR0000274785</org_study_id>
    <secondary_id>U01CA062475</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>NABTT-2002</secondary_id>
    <secondary_id>JHOC-NABTT-2002</secondary_id>
    <secondary_id>ALLOS-RSR13CT-001i</secondary_id>
    <nct_id>NCT00433472</nct_id>
  </id_info>
  <brief_title>MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806</brief_title>
  <official_title>Effect of RSR13 on T2 and T2* Cranial MRI Images: An Imaging Companion Study to NABTT 9806</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as MRI, may help doctors learn how efaproxiral works&#xD;
      in the brain and help plan the best treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is using MRI to evaluate the effect of efaproxiral on the brain&#xD;
      in patients with recurrent or progressive glioma receiving treatment on clinical trial&#xD;
      NABTT-9806.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether efaproxiral has a measurable effect on the brain as shown by T2 and/or&#xD;
           T2* MRI in patients with recurrent or progressive malignant glioma enrolled on&#xD;
           NABTT-9806.&#xD;
&#xD;
        -  Determine predicted oxygenation changes based on observed T2 MRI changes in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the effects of this drug on T2 and T2* MRI relaxation times of normal areas of&#xD;
           the brain in these patients.&#xD;
&#xD;
        -  Determine baseline oxygen extraction ratios in tumors of patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine whether administration of this drug reveals any new tumor- or&#xD;
           non-tumor-related abnormalities on T2 and T2* MRI in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, pilot study.&#xD;
&#xD;
      Patients receive efaproxiral and carmustine on clinical trial NABTT-9806. During any one&#xD;
      course of treatment on that study, patients undergo MRI before oxygen administration&#xD;
      (baseline), before efaproxiral infusion, and then every 5 minutes until 1 hour after&#xD;
      efaproxiral and carmustine treatment. Data is evaluated for extent and intensity of T2/T2*&#xD;
      changes and oxygen concentration changes in both abnormal and normal brain.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-48 patients will be accrued for this study within 12-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    not enough interest&#xD;
  </why_stopped>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Measurable effect of efaproxiral on the brain as measured by T2 and/or T2* MRI</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Predicted oxygenation changes based on observed T2 MRI changes</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of efaproxiral on T2 and T2* MRI relaxation times of normal areas of the brain</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline oxygen extraction ratios in tumors</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>New tumor- or non-tumor-related abnormalities on T2 and T2* MRI</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>MRI -</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI&#xD;
Procedure/surgery magnetic resonance imaging (MRI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic resonance imaging (MRI)</intervention_name>
    <description>MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI</description>
    <arm_group_label>MRI -</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Recurrent or progressive glioma&#xD;
&#xD;
          -  Currently enrolled on clinical trial NABTT-9806&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No severe claustrophobia&#xD;
&#xD;
          -  No cardiac pacemaker&#xD;
&#xD;
          -  No MRI-incompatible metallic implant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Kleinberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <name_title>Joy Fisher</name_title>
    <organization>ABTC Consortium</organization>
  </responsible_party>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

